Study Reference Design No of Patients G-CSF Dose (μg/kg/day) Treatment Initiated Follow-Up Outcomes
[95]    (MAGIC Trial) Phase-2, Randomised, Controlled n=7 BMNC; n=3 GCSF only; n=1 control 10 for 4 days 4 days prior to PCI 6 months. GCSF treatment is safe. Increased CD34+ cell mobilization. GCSF alone has no functional benefit. BMNC transplantation significantly increased EF & ESV. Trial stopped due to significant restenosis rate.
[100] Non-randomised, Open-labelled n=14 GCSF; n=9 control 10 for 7 days 48 hours post-PCI 3 and 12 months. GCSF is safe. Increased CD34+ cells/leukocytes. Trend towards increased EF and significant increase in WMS & perfusion vs. control.
[96]
(FIRSTLINE-AMI trial)
Randomised, Controlled n=25 GCSF; n=25 control 10 for 6 days 90 minutes post-PCI 6 months. GCSF is safe. Increased CD34+ cell mobilization. EF, WMS & viability significantly improved vs. control. 4 & 5 patients in GCSF & control had restenosis, respectively.
[101] Randomised, placebo-controlled n=8 GCSF; n=8 control 5 for 4 days 37 hours post-PCI 6 months. GCSF is safe. Increased mobilization of CD34+ cells. No significant benefit with lone GCSF.
[102]        (G-CSF-STEMI Trial) Phase-2, Randomised, double-blind, placebo- controlled n=19 GCSF; n=21 control 10 for 5 days 32 hours post-PCI 3 and 6 months. GCSF is safe. Increased CD34+ cells. No functional benefit with lone GCSF. No difference if restenosis rate vs. control.
[98] (REVIVAL-2 Trial) Randomised, Placebo-controlled n=56 GCSF; n=58 control 10 for 5 days 4-5 days post-PCI 4-6 months. Angiography at GCSF is safe. Increased CD34+ cells. No functional benefit with lone GCSF. No difference in restenosis rate.
[99] (STEMMI Trial) Phase-2, randomised, double-blind, placebo-controlled n=33 GCSF; n=37 control 10 for 6 days 10-60 hours post-PCI 6 months. GCSF is safe. Increased CD34+ cells and MSCs. No functional benefit with lone GCSF. No increase in restenosis rate with GCSF.
GCSF granulocyte-colony-stimulating-factor; EF ejection fraction; WMS wall motion score; PCI percutaneous coronary intervention; BMNC bone-marrow mononuclear cells; MSC mesenchymal stem cell
Table 3: Summary of trials utilizing G-CSF to mobilize bone-marrow cells for treatment of MI.